angiotensin ii, des-phe(8)- has been researched along with Acute Liver Injury, Drug-Induced in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Gu, T; Li, Y; Ren, L; Wang, C; Yang, Y; Zheng, H | 1 |
| Liu, X; Wang, G; Wang, Y; Xiao, H; Yin, C | 1 |
2 other study(ies) available for angiotensin ii, des-phe(8)- and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Cytokines; Drugs, Chinese Herbal; Fasting; I-kappa B Kinase; Insulin Resistance; Liver; Male; NF-kappa B; Olanzapine; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled | 2021 |
Angiotensin‑(1‑7) prevents lipopolysaccharide‑induced hepatocellular inflammatory response by inhibiting the p38MAPK/AP‑1 signaling pathway.
Topics: Angiotensin I; Animals; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Gene Expression Regulation; Hepatocytes; Lipopolysaccharides; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Protective Agents; Rats; Signal Transduction; Transcription Factor AP-1 | 2018 |